AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 3.27 million shares for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-03.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2015-03-03
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 3.27M shares, a 168.78% increase from fiscal 2013.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 1.22M shares, a 55.01% decline from fiscal 2012.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 2.71M shares, a 39.15% decline from fiscal 2011.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2011 was 4.45M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|
| 2014-12-31 | 3.27M shares 10-K · filed 2015-03-03 |
| 2013-12-31 | 1.22M shares 10-K · filed 2014-02-27 |
| 2012-12-31 | 2.71M shares 10-K · filed 2013-02-28 |
| 2011-12-31 | 4.45M shares 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |